Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Ribociclib Succinate (LEE011): CDK4/6 Inhibitor for Cancer R

    2026-06-22

    Ribociclib Succinate (LEE011): Precision CDK4/6 Inhibition in Cancer Research

    Executive Summary: Ribociclib succinate (LEE011 succinate) is a highly selective cyclin-dependent kinase 4/6 inhibitor, primarily utilized in preclinical and translational cancer research targeting HER2-positive metastatic breast cancer cells (APExBIO product information). By arresting the cell cycle at the G1 phase, it prevents proliferation of malignant cells. The compound is most effective when used in combination with endocrine therapies or aromatase inhibitors to enhance antineoplastic response. Its solubility profile is well characterized, ensuring reproducible dosing in cell proliferation assays. Evidence supports its role as a benchmark tool for dissecting cell cycle regulation in advanced cancer models (see application guide).

    Biological Rationale

    Aberrant cell cycle progression is a hallmark of cancer, often driven by dysregulation of cyclin-dependent kinases (CDKs) such as CDK4 and CDK6. In HER2-positive metastatic breast cancer, overactivation of these kinases promotes unchecked proliferation. Pharmacological blockade of CDK4/6 interrupts the cyclin D1- and D3-mediated phosphorylation cascade required for G1/S transition, providing a rational target for antineoplastic intervention. Ribociclib succinate, developed as LEE011, offers selective inhibition, allowing researchers to probe the mechanistic underpinnings of cell cycle control with minimal off-target effects (see protocol guide). This article extends prior application notes by integrating solubility, workflow, and benchmark data for more robust experimental design.

    Mechanism of Action of Ribociclib succinate

    Ribociclib succinate exerts its effect by selectively binding and inhibiting cyclin D1/CDK4 and cyclin D3/CDK6 complexes. This inhibition halts phosphorylation of the retinoblastoma (Rb) protein, a key checkpoint regulator, thereby preventing progression from G1 to S phase. The result is induction of cell cycle arrest and suppression of cell proliferation in targeted cancer cell lines. The specificity for CDK4/6 distinguishes it from broader-spectrum kinase inhibitors, reducing confounding cellular responses in mechanistic studies (APExBIO). The action is reversible and dose-dependent, supporting its utility in both transient and sustained inhibition protocols.

    Evidence & Benchmarks

    • Ribociclib succinate achieves ≥25.85 mg/mL solubility in DMSO at room temperature; in water, ≥5.19 mg/mL can be achieved with ultrasonic assistance (product specifications).
    • In simulated gastric fluid (pH 1.2), solubility is 814.05 μg/mL; in intestinal fluid (pH 6.5) 494.71 μg/mL; and at pH 6.8, 463.20 μg/mL (APExBIO).
    • Clinical oral dosing corresponds to 600 mg/day, delivered as 200 mg film-coated tablets, with no significant difference in absorption when taken with or without food (label information).
    • Co-administration with acid-reducing agents does not necessitate dose adjustment, as solubility and absorption are not significantly affected (APExBIO).
    • Purity of supplied Ribociclib succinate exceeds 98.00%, ensuring batch-to-batch consistency for cell proliferation and cell cycle pathway assays (product profile).
    • Combination with endocrine monotherapy or aromatase inhibitors amplifies antineoplastic efficacy over monotherapy alone in HER2-positive models (application guide).

    Applications, Limits & Misconceptions

    Ribociclib succinate is primarily used in cancer research as a selective CDK4/6 inhibitor, facilitating mechanistic studies of cell cycle regulation and supporting the development of antineoplastic agents. Its robust solubility profile and purity make it suitable for a variety of cell viability and cell proliferation assays. The compound is not intended for diagnostic or clinical use, and application outside preclinical research is not supported by available data (APExBIO).

    While prior articles such as "Optimizing Cancer Research with LEE011 Succinate CDK Inhibitor" discussed reproducibility and workflow enhancements, this dossier expands by detailing solubility, absorption, and combinatorial strategies for translational research.

    Common Pitfalls or Misconceptions

    • Ribociclib succinate is not effective as a monotherapy in all breast cancer subtypes; combinatorial regimens are recommended for HER2-positive lines (see application guide).
    • It is not suitable for diagnostic or therapeutic use in humans; research use only (APExBIO).
    • Long-term storage of Ribociclib succinate solutions is not recommended, as stability may be compromised; solid-state storage at -20°C is advised (APExBIO).
    • Solubility in ethanol is negligible; DMSO is preferred for stock solutions (APExBIO).
    • Its selectivity does not extend to all CDK family members; off-target kinase inhibition is minimal but not absent—confirm specificity in each model (protocol guide).

    Workflow Integration & Parameters

    For reproducible results in cancer research, standardized handling and dosing protocols are essential. APExBIO supplies Ribociclib succinate (SKU B1084) at ≥98.00% purity, supporting cell cycle pathway inhibition assays, cell proliferation assays, and combinatorial drug screening.

    Protocol Parameters

    • Solubility: Dissolve in DMSO to ≥25.85 mg/mL at room temperature; for aqueous applications, use ultrasonic assistance to achieve ≥5.19 mg/mL.
    • Physiological relevance: Simulate gastric (pH 1.2, 814.05 μg/mL) and intestinal (pH 6.5, 494.71 μg/mL) conditions to optimize in vitro dosing strategies.
    • Recommended dosing: Use at concentrations corresponding to clinical exposure (up to 600 mg/day oral equivalent), scaling according to cell line sensitivity and proliferation rate.
    • Combination protocols: Pair with endocrine monotherapy or aromatase inhibitors for maximal cell cycle arrest in HER2-positive breast cancer models.
    • Storage: Keep solid Ribociclib succinate at -20°C; prepare fresh working solutions before use.
    • Inter-assay consistency: Validate batch purity (>98%) and solubility before each experimental series.

    For advanced workflow enhancement, see "Applied Workflows with LEE011 Succinate", which details hands-on protocol modifications for HER2-positive models; this article further contextualizes those recommendations by clarifying solubility and dosing benchmarks.

    Conclusion & Outlook

    Ribociclib succinate (LEE011 succinate) from APExBIO remains a cornerstone CDK inhibitor for dissecting cell cycle regulation and optimizing antineoplastic strategies in preclinical cancer research. Its selectivity, validated solubility, and compatibility with combination therapies enable high-confidence mechanistic studies in HER2-positive breast cancer models. Future research will benefit from protocol harmonization and continued benchmarking of cell proliferation assay outcomes. These advances will facilitate translation from bench to next-generation therapeutic development. For further troubleshooting and scenario-based guidance, see "Optimizing Cell Cycle Research with Ribociclib succinate", which complements this dossier by focusing on laboratory reproducibility and interpretability.